Medicure announced that its subsidiary Medicure International has acquired an exclusive license from a large multinational pharmacompany to sell and market a branded cardiovascular drug for the treatment of patients with primary hyperlipidemia or mixed dyslipidemia, in the United States and its territories.  The licensing agreement is for a term of seven years with extensions to the term available.

The cardiovascular drug was approved earlier in 2017 by the US Food and Drug Administration (FDA) for sale and marketing in the United States and the Company intends to launch the product using its existing commercial sales force and infrastructure with a target commercial launch date in the first half of 2018.

"This licensing agreement, similar to our recent licensing of Prexxartan, fits well with Medicure's mission of being a significant cardiovascular pharmaceutical company focused on the US market," commented Medicure's president and chief executive officer, Dr. Albert D. Friesen.  "This will further add to Medicure's revenue in the near term and utilizes the current commercial infrastructure in place for Aggrastat (tirofiban hydrochloride)."